PHESGO
PeakmAbBLASUBCUTANEOUSINJECTABLE
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
PHESGO by Roche is (subdomain ii) of her2 and, thereby, blocks ligand-dependent heterodimerization of her2 with other her family members, including egfr, her3 and her4. First approved in 2020.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHESGO is a fixed-dose combination subcutaneous injection containing pertuzumab, trastuzumab, and hyaluronidase-zzxf, three HER2-targeted monoclonal antibodies and an enzyme. It is indicated for HER2-positive breast cancer patients and works by antagonizing the HER2/neu receptor to inhibit tumor growth and proliferation.
$0.001BPart D
PeakPHESGO is in peak commercial lifecycle with modest spending but is part of Roche's larger HER2 franchise, suggesting stable team size and potential for supporting roles across multiple oncology products.
Mechanism of Action
(subdomain II) of HER2 and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3 and HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through two major signaling pathways, mitogen-activated protein (MAP)…
Indications
Worked on PHESGO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.